Published September 6, 2016 | Version v1
Journal article Open

A STUDY COMPARING THE CLINICAL EFFICACY OF ORAL ANTI-DIABETIC AGENT WITH GLYCOSYLATED HAEMOGLOBIN (HbA1c) LEVELS IN TYPE II DIABETES MELLITUS

Creators

  • 1. Department of Pharm-D & Pharmacy Practice, Malla Reddy Institute of Pharmaceutical Sciences, Hyderabad, Telangana

Description

Background: Type II diabetes mellitus is a chronic metabolic disease in which there are high levels of glucose (sugar) in the blood. It is a condition characterized by high blood glucose level is caused by either a lack of insulin in the body or the body is unable to use insulin efficiently. With type II diabetes, the body either doesn't produce enough insulin, or it resists insulin.HbA1c levels are reflective of blood glucose levels over the past 6-8 weeks and don’t reflect daily ups and downs of blood glucose.

Objective: A study was conducted to compare the clinical efficacy of oral hypoglycemic agents in type II diabetes patients by using HbA1c as a diagnostic test to predict clinical outcome. And also to identify those with or at a higher risk for developing macro and micro-vascular disease associated with diabetes.

Method: A “descriptive, observational randomized& prospective study” was carried out to find the Clinical efficacy of oral hypoglycemic agents on type II diabetes patients by routinely monitoring HbA1c levels in the hospital for every 6months from Nov2012-April2016.

Result & Conclusion: It was found that the prevalence of type II diabetes is more common in women’s that compared to men’s .There was a significant reduction in glycosylated hemoglobin by considering the clinical efficacy of oral hypoglycemic agents by routinely monitoring the integrated index and changes in the baseline with the drug, which lead to decrease in HbA1c levels in Type II diabetes patients.

Key Words: Oral Hypoglycemic Agents, Type II Diabetes Mellitus, Reduction in Glycosylated Hemoglobin & Body Mass Index.      

Background: Type II diabetes mellitus is a chronic metabolic disease in which there are high levels of glucose (sugar) in the blood. It is a condition characterized by high blood glucose level is caused by either a lack of insulin in the body or the body is unable to use insulin efficiently. With type II diabetes, the body either doesn't produce enough insulin, or it resists insulin.HbA1c levels are reflective of blood glucose levels over the past 6-8 weeks and don’t reflect daily ups and downs of blood glucose.

Objective: A study was conducted to compare the clinical efficacy of oral hypoglycemic agents in type II diabetes patients by using HbA1c as a diagnostic test to predict clinical outcome. And also to identify those with or at a higher risk for developing macro and micro-vascular disease associated with diabetes.

Method: A “descriptive, observational randomized& prospective study” was carried out to find the Clinical efficacy of oral hypoglycemic agents on type II diabetes patients by routinely monitoring HbA1c levels in the hospital for every 6months from Nov2012-April2016.

Result & Conclusion: It was found that the prevalence of type II diabetes is more common in women’s that compared to men’s .There was a significant reduction in glycosylated hemoglobin by considering the clinical efficacy of oral hypoglycemic agents by routinely monitoring the integrated index and changes in the baseline with the drug, which lead to decrease in HbA1c levels in Type II diabetes patients.

Key Words: Oral Hypoglycemic Agents, Type II Diabetes Mellitus, Reduction in Glycosylated Hemoglobin & Body Mass Index.      

Files

232.pdf

Files (1.2 MB)

Name Size Download all
md5:59b0743fc20ee9407245c93a1396474f
1.2 MB Preview Download

Additional details

References

  • 1. American Diabetes Association.2016 American Diabetes Association (ADA) Diabetes Guidelines
  • 2. U.S. National Library of Medicine,PubMed health
  • 3. Medline plus and Med India HbA1c calculator.
  • 4. TheNational Diabetes Services Scheme (NDSS) by Diabetes Australia.
  • 5. Centers for Disease Control and Prevention (CDCP), History of diabetes foot ulcer among persons with diabetes, United States, 2000-2002, Morbidity & Mortality Weekly Report. 2003; 52: 1098-1102.
  • 6. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025.
  • 7. Prevalence and projections, Diabetes Care 1998; 21: 1414-1431.
  • 8. Zimmet P. Globalization, colonization, and the chronic disease epidemic: J Med 2000; 247: 301-310.
  • 9. World Health Organization Expert Committee on Diabetes Mellitus,2ndWHOTechnical Report,Series 310,Geneva,World Health Organization, 1965.
  • 10. Inzucchi S E, Bergenstal R M, Buse JB, et al; Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Diabetes Care 2015; 38: Page Number 140-9.
  • 11. Rozenfeld Y, Hunt J S, Plauschinat C, Wong K S; Oral anti-diabetic medication adherence & glycemic control in managed care 2008; 14:71-5.
  • 12. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Report of the expert committee on the diagnosis and classification of Diabetes Mellitus. Diabetes Care 1997; vol20, page1183-1197.
  • 13. Beverley B, Eschwège E. The diagnosis and classification of diabetes& impaired glucose tolerance, Textbook of Diabetes 1 Ed.John C Pickup and Gareth Williams Third edition; Chapter 2, pg2.1-2.11, 2003.
  • 14. Lindberg G, Lindblad U, Melander A; Sulfonylureas for treating type 2 diabetes mellitus. Cochrane Database Systemic Review, volume 3, 2004.
  • 15. Bearse M A Jr, Han T, Schneck M E, et al.; Local multifocal oscillatory potential abnormalities in diabetes & early diabetic retinopathy,Ophthalmic Science,2004; 45,pg 3259-3265.
  • 16. Hove M N, Kristensenet. al; the prevalence of retinopathy in an unselected population of type 2 diabetes patients, Denmark, Acta Ophthalmol Scand, 2004; 82,pg443-448.
  • 17. Seki M, Tanaka T, Nawa H, et al. ;Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats, Diabetes 2004; 53,pg 2412-2419.
  • 18. Moran A, Palmas W, Field L, et al. ;Cardiovascular autonomic neuropathy is associated with micro-albuminuria in older patients with type 2 diabetes, Diabetes care 2004; 27,pg 972-977.
  • 19. Shukla N, Angelini G D, Jeremy JY, et al; Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes, Diabetologia 2003; 46,pg766-772.
  • 20. Svensson M, Eriksson J W, Dahlquist G; Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: a population-based study in northern Sweden. Diabetes Care 2004; 27, pg955-962.
  • 21. Saely C H, Aczel S, Marte T, et al. ;Cardiovascular complications in type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetes state, Diabetologia 2004; 47,pg145-146.
  • 22. Wallace C, Reiber G E, Le Master J, et al. ;Incidence of falls, risk factors for falls, and fall-related factures in individuals with diabetes and a prior foot ulcer, Diabetes Care 2002; 25,page 1983-1986.
  • 23. Amos A, McCarty D, ZimmetP et al.; The rising global burden of diabetes and its complications, estimates, and projections to the year 2010,Diabetic Med 1997; 14: S1-S85.
  • 24. National Diabetes Data Group; Classification&diagnosis of diabetes mellitus and other categories of glucose intolerance, Diabetes 1979; 18, pg1039-1057.
  • 25. World Health Organization Expert Committee on Diabetes Mellitus;Second WHO Technical Report,Series646, Geneva-World Health Organization 1980.
  • 26. World Health Organization Study Group,DiabetesMellitus,WHO Technical Report,Series727, Geneva,World Health Organization, 1985.
  • 27. World Health Organization Consultation; Definition, Diagnosis and Classification of Diabetes Mellitus andits Complications;Diagnosis, classification of Diabetes Mellitus, Report of a WHO Consultation, Geneva: World Health Organization, 1999.
  • 28. The National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda
  • 29. Rana Ibrahim ,oral hypoglycemic agents ,Vol2 ,Supplement 1, 2010